Jean K Ho1, Daniel A Nation2. 1. Department of Psychology, University of Southern California, Los Angeles, CA, USA. Electronic address: jeanho@usc.edu. 2. Department of Psychology, University of Southern California, Los Angeles, CA, USA. Electronic address: danation@usc.edu.
Abstract
OBJECTIVES: To explore effects of the brain renin-angiotensin system (RAS) on cognition. DESIGN: Systematic review of experimental (non-human) studies assessing cognitive effects of RAS peptides angiotensin-(3-8) [Ang IV] and angiotensin-(1-7) [Ang-(1-7)] and their receptors, the Ang IV receptor (AT4R) and the Mas receptor. RESULTS: Of 450 articles identified, 32 met inclusion criteria. Seven of 11 studies of normal animals found Ang IV had beneficial effects on tests of passive or conditioned avoidance and object recognition. In models of cognitive deficit, eight of nine studies found Ang IV and its analogs (Nle1-Ang IV, dihexa, LVV-hemorphin-7) improved performance on spatial working memory and passive avoidance tasks. Two of three studies examining Ang-(1-7) found it benefited memory. Mas receptor removal was associated with reduced fear memory in one study. CONCLUSION: Studies of cognitive impairment show salutary effects of acute administration of Ang IV and its analogs, as well as AT4R activation. Brain RAS peptides appear most effective administered intracerebroventricularly, close to the time of learning acquisition or retention testing. Ang-(1-7) shows anti-dementia qualities.
OBJECTIVES: To explore effects of the brain renin-angiotensin system (RAS) on cognition. DESIGN: Systematic review of experimental (non-human) studies assessing cognitive effects of RAS peptides angiotensin-(3-8) [Ang IV] and angiotensin-(1-7) [Ang-(1-7)] and their receptors, the Ang IV receptor (AT4R) and the Mas receptor. RESULTS: Of 450 articles identified, 32 met inclusion criteria. Seven of 11 studies of normal animals found Ang IV had beneficial effects on tests of passive or conditioned avoidance and object recognition. In models of cognitive deficit, eight of nine studies found Ang IV and its analogs (Nle1-Ang IV, dihexa, LVV-hemorphin-7) improved performance on spatial working memory and passive avoidance tasks. Two of three studies examining Ang-(1-7) found it benefited memory. Mas receptor removal was associated with reduced fear memory in one study. CONCLUSION: Studies of cognitive impairment show salutary effects of acute administration of Ang IV and its analogs, as well as AT4R activation. Brain RAS peptides appear most effective administered intracerebroventricularly, close to the time of learning acquisition or retention testing. Ang-(1-7) shows anti-dementia qualities.
Authors: J W Wright; A V Miller-Wing; M J Shaffer; C Higginson; D E Wright; J M Hanesworth; J W Harding Journal: Brain Res Bull Date: 1993 Impact factor: 4.077
Authors: Alene T McCoy; Caroline C Benoist; John W Wright; Leen H Kawas; Jyote M Bule-Ghogare; Mingyan Zhu; Suzanne M Appleyard; Gary A Wayman; Joseph W Harding Journal: J Pharmacol Exp Ther Date: 2012-10-10 Impact factor: 4.030
Authors: Zachary A Marcum; Yongmei Li; Sei J Lee; Michael A Steinman; Laura Graham; Bocheng Jing; Kathy Fung; Carmen A Peralta; Michelle C Odden Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Charles E Evans; James S Miners; Giulia Piva; Christine L Willis; David M Heard; Emma J Kidd; Mark A Good; Patrick G Kehoe Journal: Acta Neuropathol Date: 2020-01-25 Impact factor: 15.887
Authors: Jean K Ho; Frank Moriarty; Jennifer J Manly; Eric B Larson; Denis A Evans; Kumar B Rajan; Elizabeth M Hudak; Lamiaa Hassan; Enwu Liu; Nobuyuki Sato; Naoyuki Hasebe; Danielle Laurin; Pierre-Hugues Carmichael; Daniel A Nation Journal: Hypertension Date: 2021-06-21 Impact factor: 9.897
Authors: Caglar Cosarderelioglu; Lolita S Nidadavolu; Claudene J George; Esther S Oh; David A Bennett; Jeremy D Walston; Peter M Abadir Journal: Front Neurosci Date: 2020-09-30 Impact factor: 4.677
Authors: Jan Willem van Dalen; Zachary A Marcum; Shelly L Gray; Douglas Barthold; Eric P Moll van Charante; Willem A van Gool; Paul K Crane; Eric B Larson; Edo Richard Journal: Neurology Date: 2020-11-05 Impact factor: 9.910